PYXS News and Press, Pyxis Oncology Inc.

BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to continue execution and advancement of the Company’s strategic and clini...

VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants confront a looming $170 billion patent cliff [1] . This massive pressure is forcing a ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The war on cancer is moving into a high-tech era of molecular-guided defense. The genomics in cancer care market is now projected to hit a staggering $69.16 billion by 2032 as precis...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 7.4% to $3.48 on volume of 535,971,389 shares Vivakor Inc. (VIVK) rose 47.3% to $0.0751 on volume of 233,997,647 shares Canopy Growth Corporation (CGC) fell 12.0% to $1.69 on volum...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 8.9% to $3.425 on volume of 489,648,690 shares Canopy Growth Corporation (CGC) fell 9.9% to $1.73 on volume of 196,690,793 shares urban-gro Inc. (UGRO) rose 18.2% to $0.3499 on vol...

2025-12-18 14:57:37 ET Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma December 18, 2025 8:30 AM EST... Read the full article on Seeking Alpha For further details see: Pyxis Oncology, ...

2025-12-18 11:53:31 ET More on Pyxis Oncology Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma - Slideshow Seeking Alpha’s Quant Rating on Pyxis Oncology Historical earni...

46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in combination with KEYTRUDA ® (pembrolizumab) in 1L/2L+ R/M HNSCC at 3.6 mg/kg and 4.4 mg...

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcoming investor conferences in November 2025: ...

2025-11-03 07:46:49 ET More on Pyxis Oncology Pyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade) Seeking Alpha’s Quant Rating on Pyxis Oncology Historical earnings data for Pyxis Oncology Financial information for Pyxis Onco...